Retinoblastoma in Ethiopian Children: Imaging Findings and Staging

埃塞俄比亚儿童视网膜母细胞瘤:影像学表现和分期

阅读:1

Abstract

BACKGROUND: Retinoblastoma is the most prevalent intraocular retinal malignancy in children worldwide. Accurate staging is critical for treatment planning and relies heavily on radiologic imaging and clinical findings. This study aims to evaluate imaging patterns and staging of retinoblastoma in children at Tikur Anbessa Specialized Hospital (TASH). MATERIALS AND METHODS: This cross-sectional study analyzed retrospective data from TASH between September 2018 and September 2021. It focused on patients diagnosed with retinoblastoma who underwent Computed Tomography (CT) scans or Magnetic Resonant Imaging (MRI) and had pathology results available. Two radiologists, each with over 10 years of experience, independently reviewed the scans. Supplementary data were gathered from the pediatric oncology unit registry using structured questionnaires. The International Retinoblastoma Staging System (IRSS) was used to stage extraocular disease based on cross-sectional imaging and the International Intraocular Retinoblastoma Classification (IIRC) for intraocular disease classification. RESULTS: Eighty-three patients were included, with 42 (50.6%) males and 41 (49.4%) females. The mean age at presentation was 3.4 ± 2 years. The most common clinical symptoms were proptosis (42 patients, 50.6%) and leukocoria (37 patients, 44.6%). Clinical staging revealed 63 (75.9%) patients in Group E, 19 (22.9%) in Group D, and 1 (1.2%) in Group C according to IIRC. Stage IV disease was predominant, with 33 (39.2%) in Stage IVA and 18 (21.4%) in Stage IVB according to IRSS. CONCLUSION: Most patients presented with advanced retinoblastoma, particularly Stage IV. This underscores the need for community awareness of early signs and symptoms of retinoblastoma, promoting timely medical consultation.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。